German drugmaker Merck KGaA welcomed guildelines recommending that newly-diagnosed patients with diabetes should be treated with its drug Glucophage (metformin), unless it is contraindicated, in conjunction with lifestyle modification.
The new consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, released at a recent meeting in Copenhagen, Denmark, urges that initiation of metformin should no longer be delayed until lifestyle modification (weight loss and increased activity) fails to adequately control glycemia.
Traditionally, guidelines have recommended lifestyle change as the first step in intervention to reduce glycemia. However, the ADA/EASD expert panel recognized that, alone, this often fails to achieve or maintain metabolic goals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze